Patent ID: 11926843
Assignee: LIFEEDIT THERAPEUTICS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 4:
5. The vector of claim 4, wherein said vector further comprises at least one nucleotide sequence encoding a guide RNA, and wherein the guide RNA comprises:
(a) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 12, wherein the RGN polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 11;
(b) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 28, wherein the RGN polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 27;
(c) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 46, wherein the RGN polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 45;
(d) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 55, wherein the RGN polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 54;
(e) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 2, wherein the RGN polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 1;
(f) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 20, wherein the RGN polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 19; or
(g) a CRISPR RNA comprising a CRISPR repeat sequence having at least 95% sequence identity to SEQ ID NO: 37, wherein the RGN polypeptide comprises an amino acid sequence set forth as SEQ ID NO: 36.